Dow Jones
39.829,27 +271,16 (+0,69%) Nasdaq
16.727,61 +216,43 (+1,31%) Nikkei 225
38.385,73 +29,67 (+0,08%) EUR/USD
1,0878 +0,0057 (+0,52%) Bitcoin EUR
59.954,56 +3.517,98 (+6,23%) CMC Crypto 200
1.373,90 +105,95 (+8,35%)
Incyte Corporation (ICY.F)
| Chiusura precedente | 53,00 |
| Aperto | 52,60 |
| Denaro | 52,58 x 20000 |
| Lettera | 52,62 x 20000 |
| Min-Max giorno | 52,60 - 52,60 |
| Intervallo di 52 settimane | 47,11 - 60,74 |
| Volume | |
| Media Volume | 33 |
| Capitalizzazione | 11,827B |
| Beta (5 anni mensile) | 0,69 |
| Rapporto PE (ttm) | 17,19 |
| EPS (ttm) | 3,06 |
| Prossima data utili | 30 lug 2024 - 05 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 101,27 |
GlobeNewswireGlobal CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032
PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic
GlobeNewswireKnight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil
MONTREAL, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has submitted a marketing authorization application for pemigatinib to ANVISA, the Brazilian health regulatory agency, under the rare diseases approval pathway, for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor recepto
